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ORIGINAL RESEARCH
Cell-Specific Gene Deletion Reveals the 
Antithrombotic Function of COX1 and Explains 
the Vascular COX1/Prostacyclin Paradox
Jane A. Mitchell, Fisnik Shala, Youssef Elghazouli, Timothy D. Warner, Carles Gaston-Massuet, Marilena Crescente,  
Paul C. Armstrong, Harvey R. Herschman, Nicholas S. Kirkby
RATIONALE: Endothelial cells (ECs) and platelets, which respectively produce antithrombotic prostacyclin and prothrombotic 
thromboxane A2, both express COX1 (cyclooxygenase1). Consequently, there has been no way to delineate any antithrombotic 
role for COX1-derived prostacyclin from the prothrombotic effects of platelet COX1. By contrast, an antithrombotic role for 
COX2, which is absent in platelets, is straightforward to demonstrate. This has resulted in an incomplete understanding of 
the relative importance of COX1 versus COX2 in prostacyclin production and antithrombotic protection in vivo.
OBJECTIVE: We sought to identify the role, if any, of COX1-derived prostacyclin in antithrombotic protection in vivo and compare 
this to the established protective role of COX2.
METHODS AND RESULTS: We developed vascular-specific COX1 knockout mice and studied them alongside endothelial-specific 
COX2 knockout mice. COX1 immunoreactivity and prostacyclin production were primarily associated with the endothelial 
layer of aortae; freshly isolated aortic ECs released >10-fold more prostacyclin than smooth muscle cells. Moreover, aortic 
prostacyclin production, the ability of aortic rings to inhibit platelet aggregation and plasma prostacyclin levels were reduced 
when COX1 was knocked out in ECs but not in smooth muscle cells. When thrombosis was measured in vivo after FeCl3 
carotid artery injury, endothelial COX1 deletion accelerated thrombosis to a similar extent as prostacyclin receptor blockade. 
However, this effect was lost when COX1 was deleted from both ECs and platelets. Deletion of COX2 from ECs also 
resulted in a prothrombotic phenotype that was independent of local vascular prostacyclin production.
CONCLUSIONS: These data demonstrate for the first time that, in healthy animals, endothelial COX1 provides an essential 
antithrombotic tone, which is masked when COX1 activity is lost in both ECs and platelets. These results help us define a 
new 2-component paradigm wherein thrombotic tone is regulated by both COX1 and COX2 through complementary but 
mechanistically distinct pathways.
VISUAL OVERVIEW: An online visual overview is available for this article.
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Prostacyclin is one of the body's fundamental car-dioprotective hormones and has a powerful anti-thrombotic role. Loss of the prostacyclin receptor 
(I-prostanoid receptor [IP]) in mice increases thrombosis1 
and loss-of-function IP mutations in man are associ-
ated with atherothrombotic risk.2 Prostacyclin formation 
requires activation of COX (cyclooxygenase) enzymes, for 
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in most tissues, including the vasculature, while signifi-
cant levels of COX2 are constitutively expressed only in 
discreet regions including the kidney.4
Within large arteries, both endothelial cells (ECs) and 
smooth muscle cells (SMCs) can produce prostacyclin, 
although the endothelium is assumed to be the dominant 
site.3,5 COX1 drives prostacyclin release in freshly iso-
lated arteries and circulating levels of prostacyclin's spon-
taneous breakdown product (6-ketoPGF1α).
4,6,7 A role 
for COX2 in systemic prostacyclin production has been 
inferred from measurements of the urinary prostacyclin 
metabolite, PGI-M,8 and data from cultured cells/tissues.9 
However, these studies must be interpreted with caution 
since PGI-M does not necessarily reflect systemic vas-
cular production10 and COX2 is rapidly induced in vitro.6
Despite its unclear contribution to systemic vascular pros-
tacyclin production, an antithrombotic influence of constitu-
tive COX2 is readily observed in COX2-deficient mice8,11 and 
in patients taking COX2 inhibitors.3,12 By contrast, no physi-
ological antithrombotic role for COX1 in vascular cells has 
been shown in integrated in vivo models to date. Where this 
question has been studied, global COX1 inhibition reduces 
thrombosis.13,14 These observations leave a paradoxical 
situation wherein we know vascular COX1 generates the 
bulk of arterial prostacyclin but it has no proven function in 
antithrombotic protection. COX1 is also expressed in plate-
lets where it is coupled to the powerful platelet activator, 
thromboxane A2. As such, the vascular COX1/prostacyclin 
paradox has 2 possible answers, either (1) the importance 
of vascular COX1-derived prostacyclin has been overstated 
and it does not appreciably limit thrombosis or (2) when 
COX1 is inhibited globally, the phenotype is so dominated by 
loss of platelet COX1 that an important antithrombotic role 
for vascular COX1-derived prostacyclin is masked.
Using previous experimental models, it has not been 
possible to separate vascular and platelet COX1 activity. 
To address this, here we have generated the first avail-
able floxed Ptgs1 mouse line and used this as the basis 
for conditional knockout strains wherein COX1 is specifi-
cally deleted from (1) SMCs, (2) ECs or (3) both ECs and 
platelets. Using these animals, along with established 
endothelial COX2 knockout models, we have performed 
studies to identify and compare the role of vascular COX 
isoforms in prostacyclin generation and thrombosis. 
These studies demonstrate for the first time a powerful 
antithrombotic role for vascular COX1 that acts in con-
cert with the cardioprotective functions of COX2.
METHODS
Detailed methods are described in the Online Data Supplement. 
The data that support the findings of this study are available 
from the corresponding author on reasonable request.
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Novelty and Significance
What Is Known?
• COX (cyclooxygenase) enzymes exist as 2 isoforms 
and generate prostanoid mediators including anti-
thrombotic prostacyclin in blood vessels and prothrom-
botic thromboxane in platelets.
• COX2 is sparsely expressed in most blood vessels but 
has a clear antithrombotic role, evidenced by the car-
diovascular side effects of drugs that inhibit COX2.
• By contrast, COX1 is the principal driver of prostacyclin 
in most blood vessels but paradoxically no antithrom-
botic role for COX1 has been demonstrated to date.
What New Information Does This Article  
Contribute?
• COX1 expressed in endothelial cells drives vascular 
and circulating prostacyclin with little role for either 
COX1 in smooth muscle or COX2 in endothelial cells.
• Endothelial cell COX1 produces an antithrombotic 
effect, but this is masked by platelet COX1-derived 
thromboxane.
• Endothelial COX2 provides an equally powerful anti-
thrombotic tone, which occurs through an alternative 
mechanism, independent of local vascular prostacyclin.
Although the antithrombotic pedigree of prostacyclin is 
well established, the role of COX1 in mediating prosta-
cyclin production and thus antithrombotic protection has 
remained controversial for almost 20 years. In the current 
study, we have generated a range of novel cell-specific 
knockout mouse models to provide the first demonstration 
that endothelial COX1 provides a fundamental antithrom-
botic pathway mediated by vascular prostacyclin release. 
This functions to complement the well-known antithrom-
botic activity of endothelial COX2, which occurs through 
an equally powerful but distinct mechanism. Together, 
these findings emphasise that it is essential to consider 
the roles of COX1 and COX2 equally if we are to fully 
understand the cardiovascular biology of COX enzymes 
and the pharmacology of drugs which act upon them.
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Briefly, cell-specific COX1 and COX2 knockout mice were 
generated using a Cre-loxP approach. Animal work was per-
formed in accordance with relevant legislation and ethical 
review. COX expression was analyzed using immunohisto-
chemistry and confocal microscopy. Vascular cells were iso-
lated using fluorescence-activated cell sorting. Prostanoids 
were measured by ELISA. Thrombosis in vivo was measured 
using a FeCl3 carotid artery injury model. Data are presented as 
mean±SEM for n biological replicates.
RESULTS
Relative Role of ECs Versus SMCs in 
Prostacyclin Generation
To establish the role of vascular COX1 in antithrombotic 
protection, we first identified the relative contributions of 
COX1 in ECs and SMCs to arterial prostacyclin produc-
tion. We used confocal microscopy Z-stacking to cre-
ate full thickness 3-dimensional representations of the 
mouse aortic wall. Intense COX1 but not COX2 staining 
was apparent in the endothelium, consistent with our 
previous findings6; with little expression of either isoform 
in smooth muscle layers (Figure 1A; Online Figures I and 
II). This staining was blocked by an excess of the immun-
ising peptide confirming its specificity (Figure 1A; Online 
Figure I). In agreement, when aortae were mechanically 
denuded of ECs, their ability to synthesise prostacyclin 
was reduced by ≈80% (Figure 1B). This observation has 
been made many times before, originally with the discov-
ery of prostacyclin in 197615 and, while compelling, its 
interpretation is based on complete, consistent removal 
of the endothelial layer without damage to the under-
lying smooth muscle. To validate this interpretation, we 
isolated fresh aortic ECs and SMCs using fluorescence-
activated cell sorting and determined that isolated aor-
tic ECs can generate >10-fold more prostacyclin than 
SMCs when activated (Figure 1C). However, it must also 
be considered that (1) SMCs can produce prostacyclin, 
albeit in small amounts, (2) that SMCs may outnum-
ber ECs in large arteries, and (3) that the phenotype 
of SMCs varies between vascular beds. Therefore, the 
contribution to prostacyclin production in vivo may not 
Figure 1. COX1 expression and activity in vascular endothelial and smooth muscle cells.  
A, COX1 immunoreactivity was measured through aortic rings by confocal Z-stacking microscopy and staining specificity confirmed using a blocking 
peptide. B, Prostacyclin production was measured after A23187 (30 μmol/L) stimulation in adjacent aortic rings taken from individual wild-type 
mice with/without mechanical endothelial removal. C, Endothelial and smooth muscle cells were isolated in a paired fashion from single aortas of 
wild-type mice using fluorescence-activated cell sorting and arachidonic acid (30 μmol/L)-induced prostacyclin release measured by immunoassay. 
Prostacyclin release was also measured from (D) aortic smooth muscle cells from Flox COX1 Ctrl and SMC COX1 KO mice and (E) intact aortic 
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be captured in isolated vessel/cell assays. To clarify this, 
we generated smooth muscle-specific COX1 knockout 
mice (SMC COX1 KO) by crossing floxed Ptgs1 mice 
and mice carrying an Sm22a-Cre driver. Aortic vascular 
SMCs isolated from SMC KO mice (Ptgs1flox/flox;Sm22a-
Cre) lost their prostacyclin synthetic capacity (Figure 1D) 
and Ptgs1 mRNA expression (reduced 72±23% versus 
Flox COX1 Ctrl; n=2–3). In contrast, aortic ECs isolated 
from these mice showed no defect in prostacyclin pro-
duction (Flox COX1 Ctrl: 49.8±3.3 fg/cell; SMC COX1 
KO: 45.2±11.8 fg/cell; n=2–3), confirming the validity 
of the model. When prostacyclin generation was mea-
sured from intact aortic rings, SMC COX1 KO had no 
effect on prostacyclin induced by either chemical activa-
tion with Ca2+ ionophore A23187 (Figure 1E) or activa-
tion with mechanical agitation to mimic physical forces 
in the body (Flox COX1 Ctrl: 7.4±2.7 ng/mL; SMC 
COX1 KO: 6.7±1.2 ng/mL; P=0.780 by unpaired t test, 
n=5–8). Similarly, plasma levels of the stable prostacy-
clin breakdown product, 6-keto-PGF1α, an indicator of 
total vascular prostacyclin production in vivo, were not 
affected by SMC COX1 KO (Flox COX1 Ctrl: 134±8 
pg/mL; SMC COX1 KO: 135±20 pg/mL; P=0.473 by 
Mann-Whitney U test, n=8–12). Together, these obser-
vations demonstrate that smooth muscle COX1 makes 
only a very minor contribution to the total vascular pros-
tacyclin production in healthy animals. Consequently, 
a significant role for vascular smooth muscle COX1 in 
physiological prostacyclin-mediated antithrombosis can 
be excluded (although may warrant further investigation 
under conditions of vascular disease).
Generation and Validation of Endothelial COX 
Knockout Mouse Models
We therefore focused on the endothelium and generated 
3 additional conditional knockout models. The first, a 
selective endothelial COX1 knockout mouse (EC COX1 
KO), generated using an inducible VE-cadherin-CreERT2 
driver, was used to determine if vascular EC COX1 con-
tributes to prostacyclin generation and antithrombotic 
protection. The second, a combined endothelial/platelet 
COX1 knockout mouse (EC/platelet COX1 KO), was 
made to address whether an antithrombotic role of endo-
thelial COX1 is masked when COX1 is also removed 
from platelets. To generate this mouse, we took advan-
tage that Tie2/Tek is expressed in both endothelium 
and megakaryocytes; as a result, Cre expressed under 
the Tie2/Tek promoter drives deletion of gene products 
from platelets as well as ECs.16 The third, as a point of 
comparison, was a selective endothelial COX2 knockout 
mouse (EC COX2 KO) generated using the same strat-
egy as previous groups,9 by crossing floxed Ptgs2 mice 
with a Tie2/Tek-Cre driver. Compared with respective 
controls, EC COX1 KO (Ptgs1flox/flox;VE-cadherin-CreERT2), 
EC/platelet COX1 KO (Ptgs1flox/flox;Tie2-Cre), and Global 
COX1 KO (Ptgs1−/−) but not EC COX2 KO (Ptgs2flox/
flox;Tie2-Cre) mice demonstrated loss of aortic endothe-
lial COX1 immunoreactivity when evaluated by confocal 
microscopy (Figure 2A; Online Figures I and III). Because 
basal COX2 expression is not detectable in aortic endo-
thelium by this approach, to validate EC COX2 KO mice, 
we induced COX2 by overnight culture. This treatment 
resulted in robust COX2 expression which was absent in 
aortae from EC COX2 KO mice but fully retained in each 
COX1 KO strain (Figure 2B; Online Figure I). EC/plate-
let COX1 KO and Global COX1 KO mice also exhibited 
loss of platelet COX1 activity, whereas, as expected, the 
capacity of blood platelets to synthesise thromboxane 
was retained in EC COX1 KO and EC COX2 KO mice 
(Figure 2C; Online Table I).
Using these models, we determined the impact of 
endothelial COX1 and COX2 deficiency on prostacyclin 
generation. We observed ≈75% reduction in prostacyclin 
(6-keto-PGF
1α) release from Ca
2+ ionophore-activated 
aortae isolated from EC COX1 KO and EC/platelet 
COX1 KO mice and a complete loss in aortae isolated 
from Global COX1 KO mice (Figure 2D; Online Table I). 
In contrast, EC COX2 deletion had no effect on aortic 
prostacyclin release (Figure 2D; Online Table I). These 
results are consistent with previous findings that aortic 
prostacyclin synthesis requires COX14, 6, 7 and is princi-
pally associated with ECs.5 Similar results were obtained 
in each model when vessels were activated by physi-
cal force (Online Table I). However, loss of prostacyclin 
inferred from reduced immunoreactive 6-keto-PGF1α 
may not correlate with the antithrombotic function. To 
explore this question further and to validate our models, 
we set up a bioassay system where we could use the 
ability of aortic rings to inhibit platelet aggregation as a 
direct functional readout of their capacity to synthesise 
bioactive prostacyclin; analogous to the methodology 
used by Vane et al to first identify the antiplatelet effects 
of prostacyclin.15 Incubation of aortic rings from con-
trol animals with human platelet-rich plasma produced 
≈40% inhibition of aggregation (Figure 2E; Online Table 
I). This inhibitory effect was associated with aortic COX1 
products; inhibition of platelet aggregation was absent 
when Global COX1 KO aortae were used. Blocking 
platelet COX1 had no effect on the inhibitory activity of 
aortic rings in this assay (Online Figure IV) suggesting 
that transcellular metabolism of platelet-derived inter-
mediates17 cannot support prostacyclin production in 
these conditions. Aortae from EC COX1 KO and EC/
platelet COX1 KO mice demonstrated a blunted ability 
to inhibit platelet aggregation whereas EC COX2 KO 
retained their platelet inhibitory effect (Figure 2E; Online 
Table I). Across each strain, the level of platelet inhibition 
closely correlated (r2=0.96) with level of immunoreac-
tive 6-keto-PGF1α, suggesting that this effect reflects a 
loss of the capacity to synthesise bioactive prostacyclin 
(Online Figure V). Next, because local production by the 
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aorta may not fully represent prostacyclin production 
in all vascular beds, we extended our observations to 
measure plasma levels of 6-keto-PGF1α in these mouse 
models. EC COX1 KO and EC/platelet COX1 KO but not 
EC COX2 KO animals exhibited a reduction in circulating 
(6-keto-PGF1α; Figure 2F; Online Table I). As expected, 
the remaining 6-keto-PGF1α was lost in Global COX1 
KO mice, indicating that COX1 in other cell types makes 
a contribution to total synthesis.
Effect of Endothelial COX Deletion on 
Thrombus Formation In Vivo
Having shown that EC COX1 KO mice exhibit loss of arte-
rial prostacyclin production and that aortae from these 
mice lose antiplatelet activity in vitro, we used our mouse 
models to delineate the role of endothelial and platelet 
COX1 in thrombosis in vivo. Thrombosis was measured 
using a carotid artery FeCl3-injury model that has been 
Figure 2. Contribution of endothelial COX1 and COX2 to vascular and circulating prostacyclin levels.  
A, Basal COX1 immunoreactivity was examined in the endothelial cell layer of intact aortae by confocal microscopy. B, COX2 immunoreactivity 
was examined in basal conditions and after vessels were cultured to induce expression (24 h; +LPS; 1 μg/mL). Staining specificities were 
confirmed using specific blocking peptides. C, Thromboxane production was measured by immunoassay in A23187 (30 μmol/L)-stimulated 
whole blood. D, Aortic prostacyclin production was measured after A23187-stimulation by immunoassay. E, The ability of aortic rings to inhibit 
aggregation of aspirin-treated human platelets was measured by light transmission aggregometry. F, Circulating prostacyclin levels were 
measured as plasma 6-keto-PGF1α by immunoassay. In each case, data from Global COX1 KO, endothelial cell (EC) COX1 KO, EC/platelet 
(PT) COX1 KO, and EC COX2 KO are presented normalized to their respective control strains (100%). Absolute values for each strain and its 
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used previously to establish the prothrombotic effects 
of both lP receptor deletion1 and global COX2 inhibi-
tion/deletion.11,18 EC COX1 KO mice exhibited acceler-
ated thrombotic occlusion of the carotid artery following 
FeCl3 injury as compared with floxed littermate controls 
(Figure 3A), revealing the antithrombotic activity of vas-
cular COX1. This acceleration of thrombosis was similar 
to that observed when floxed control mice were treated 
acutely with the IP receptor antagonist, Ro1138452 
(Figure 3B). However, when COX1 was deleted in both 
ECs and platelets in EC/platelet COX1 KO mice, throm-
botic occlusion time was increased (Figure 3C), despite 
>80% loss of prostacyclin production from carotid artery 
rings at the site of injury (Flox COX1 Ctrl: 10.2±3.3 ng/
mL; EC/platelet COX1 KO: 2.0±1.3 ng/mL; P=0.010 
by Mann-Whitney U test; n=5–7). We compared the 
effect of these COX1 deletions to the effect of endo-
thelial COX2 deletion which, as previously reported,9,18 
accelerated thrombosis after FeCl3 injury (Figure 3D). 
However, this prothrombotic effect was not associated 
with any loss of local prostacyclin production in the 
carotid artery (Flox COX2 Ctrl: 10.6±3.4 ng/mL; EC 
COX2 KO: 10.8±2.2 ng/mL; P=0.414 by Mann-Whitney 
U test; n=6–8). Acute treatment (20 minutes; ≈10× the 
half-life of prostacyclin) of mice with a selective COX2 
inhibitor, parecoxib, to remove short-lived COX2-derived 
prostaglandins had no effect on thrombosis (Figure 3E). 
Only when parecoxib was administered chronically (5 
days), at a dose producing equivalent COX2 inhibition 
(Online Figure VI) was the established prothrombotic 
effect of COX2 inhibition seen (Figure 3F).
DISCUSSION
By the 1970s, it was firmly established that the endothe-
lium provides an antithrombotic surface. This observation 
Figure 3. Contribution of endothelial COX1 and COX2 to control of thrombotic tone.  
Thrombosis was measured using a FeCl3 carotid artery injury model in (A) Flox COX1 Ctrl, endothelial cell (EC) COX1 KO, and Flox COX-1 Ctrl 
mice treated with the selective I-prostanoid receptor antagonist Ro1138452 (Ro11; 10 mg/kg; iv, 20 min), (B) in Flox COX1 Ctrl and EC/platelet 
(PT) COX1 KO mice, (C) in Flox COX2 Ctrl and EC COX2 KO mice, and (D) in wild-type mice treated with the selective COX2 inhibitor parecoxib 
either acutely (5 mg/kg; intravenous, 20 min) or chronically (25 mg/kg/day; oral, 5 days). Representative traces inset (scale: flow, 0–2 mL/min; 
time, 0–1200 s). *P<0.05 by (A and D) Kruskal-Wallis ANOVA with Dunn posttest or (B and C) Mann-Whitney U-test.
ORIGINAL RESEARCH
Mitchell et al Antithrombotic Function of Vascular COX1
Circulation Research. 2019;125:847–854. DOI: 10.1161/CIRCRESAHA.119.314927 October 11, 2019  853
was rapidly followed by the discovery of 2 COX products 
with striking opposing effects on thrombosis: prothrom-
botic thromboxane A2 and antithrombotic prostacyclin. 
Since this time, the prostacyclin-thromboxane balance 
has become a cardinal feature of cardiovascular biology 
and underpins the pharmacology of some of the world's 
most widely used drugs including aspirin and other non-
steroidal anti-inflammatory drugs.
Beyond this simple idea, much complexity has 
emerged. The most controversial questions surround 
what role, if any, vascular COX1 plays in antithrombotic 
protection and how this complements the well-known 
antithrombotic actions of COX2 seen in animal mod-
els8,11 and patients taking COX2 inhibitors.3,12 COX1 is 
required for prostacyclin formation by most arteries.4,6,7 
However, to date, there have been no tools to dissoci-
ate vascular from platelet COX1 and, as such, no way 
to determine whether COX1-derived prostacyclin is 
physiologically important in thrombotic protection. In the 
current study, we have confirmed earlier observations 
using isolated cells,5 to show the endothelial layer is the 
principal site for prostacyclin generation and antiplatelet 
activity of intact blood vessels in vitro. Using novel condi-
tional knockout mice, we found that endothelial-specific 
COX1 deletion prevented local vascular and circulating 
prostacyclin production and produced a prothrombotic 
phenotype similar to that seen when prostacyclin recep-
tors are blocked. However, when thrombosis was studied 
in dual endothelial/platelet COX1 knockout mice the net 
effect was antithrombotic. These data demonstrate, for 
the first time, that endothelial COX1 provides an essen-
tial antithrombotic tone, but when COX1 activity is lost in 
both ECs and platelets the resulting phenotype is driven 
by loss of prothrombotic prostanoids from platelets. In 
parallel experiments using endothelial-specific COX2 
knockout mice, we observed a prothrombotic phenotype, 
in agreement with previous reports that deletion/inhi-
bition of COX2 in mice, either globally,8,11 or selectively 
from vascular cells,9,18 or renal interstitial cells increases 
thrombosis.18 However, this was not associated with any 
change in aortic, carotid, or circulating prostacyclin lev-
els, consistent with observations that constitutive COX2 
expression is restricted to specific tissues and vascular 
beds and absent in most systemic blood vessels.4 Fur-
ther, acute administration of a selective COX2 inhibitor to 
remove COX2-derived prostacyclin and other short-lived 
prostaglandins had no effect on thrombosis. Instead, and 
in agreement with published protocols,8,11 the prothrom-
botic effect of parecoxib took several days to develop. 
Therefore, the antithrombotic effect of endothelial COX2 
cannot be explained by an acute prostacyclin-mediated 
event such as platelet inhibition. It is important to note 
that in vascular disease there may be changes in the 
expression of COX isoforms that alter their relative roles 
in antithrombotic protection; however, even in severe 
atherosclerosis, COX1 remains the dominant driver of 
prostacyclin production by systemic arteries19,20 with a 
contribution from COX2 only appearing under conditions 
of endotoxemia.21
With the role for COX1 in systemic vascular prostacy-
clin production and antithrombotic protection established 
in the current study and directly compared with that of 
endothelial COX2, we now propose a 2-component 
paradigm for COX-mediated antithrombotic protection. 
We suggest that (1) COX1 expressed throughout the 
systemic vasculature generates a direct prostacyclin-
mediated inhibition of platelet reactivity and (2) COX2 
expressed in vascular and nonvascular cells in discrete 
tissue locations produces an equally powerful but indirect 
regulation of systemic thrombotic tone. These concepts 
and the availability of animal models to dissect tissue-spe-
cific roles of COX1 and COX2 should provide the impetus 
for renewed research into one of the body's most basic 
cardioprotective pathways and emphasise that, in future, 
we must consider the role of both COX isoforms equally 
if we are fully understand the cardiovascular biology of 
COX enzymes and the consequences of their inhibition.
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